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efficient or the probability.2 Menard states that “the OR can-
not take the place of a standardized logistic regression co-
efficient for valuating the strength of the influences of the
independent variables on the dependent variable, relative
to one another.” The strength of each independent variable
cannot be judged based on themagnitude of the OR, so that
a larger OR for one independent variable might not have a
stronger association than a smaller OR for another inde-
pendent variable.
The magnitude of the OR should not be used to evaluate
the strength of association for individual independent vari-
ables or predictors. In the article by Mora et al, a different
analysis is needed to assess the strength of association be-
tween the biomarkers and BMI, physical inactivity, or other
independent variables.
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In Reply: Dr Cheng raises a statistical concern regarding the
comparison of the magnitude of the ORs for BMI and physi-
cal inactivity in relation tocardiovascularbiomarkers.Weagree
that when comparing the association of 2 differentmeasures,
such as BMI and physical inactivity, with a dependent vari-
able, the 2 measures should be standardized for comparison.
Some investigators argue for using standardized regression co-
efficients when comparing the relative contributions of each
measure. However, standardized coefficients have limited ap-
plicability tononnormallydistributedpredictors.1 Inour study,
BMI and physical activity were not normally distributed. For
such analyses, it is preferable to calculate the coefficients for
quantiles of BMI and physical inactivity1 as we did in Table 4,
providing an accurate and readily interpretable comparison
of the 2 measures with respect to their associations with the
cardiovascular biomarkers. From a clinical and public health
perspective, we also chose to display the results using clini-
cal cutpoints for BMI and physical inactivity, as demon-
strated in the Figure.
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RESEARCH LETTER
Declaration of Medical Writing Assistance
in International Peer-Reviewed Publications
To the Editor:Medical researchers have an ethical and sci-
entific obligation to publish, but between one third and two
thirds of research may remain unpublished.1,2 A major rea-
son for nonpublication is lack of time,1 which may lead re-
searchers to seekmedical writing assistance. Guidelines from
journal editors3 andmedical writers4-6 encourage authors to
acknowledge medical writers. We quantified the propor-
tion of articles from international, peer-reviewed, high-
ranking journals that reported medical writing assistance.
Methods. For this descriptive study, which was con-
ducted between November 2004 and January 2005, we re-
viewed 1000 original research articles from 10 interna-
tional journals, representing different content areas (TABLE).
Selected journals had to be among the highest ranking jour-
nals in their area (based on the 2003 Institute for Scientific
Information impact factor), be peer-reviewed, publish ac-
knowledgments, and be available online and in English. Ar-
ticleswere selected in consecutive reverse order, startingwith
themost recent online edition, until we had 100 articles per
journal. Standardized definitions were used to classify ar-
ticles in terms of declared writing assistance (reference to
an individual or organization that assisted with the prepa-
ration, writing, technical editing, spelling and grammar
checking, or formatting of the manuscript) and pharma-
ceutical sponsorship (statement that research was spon-
sored by a pharmaceutical company, or if 1 or more of the
authors was a pharmaceutical company employee). Preva-
lence rates and 95% confidence intervals (CIs) were deter-
mined from logistic regression analysis using SAS version
9.1 (SAS Institute, Cary, NC).
Results. Medical writing assistance was reported in only
60 (6.0%) of 1000 articles (95%CI, 4.6%-7.7%). In the sub-
set of pharmaceutical-sponsored studies (n=102), assis-
tance was declared in 10 articles (9.8%; 95% CI, 4.8%-
17.3%). Prevalence varied among journals, from aminimum
of 0% to a maximum of 11%.
Comment. To our knowledge, this is the first quantifica-
tion of the prevalence of declared medical writing assis-
tance in a large cohort of original research articles from in-
ternational, high-ranking, peer-reviewed journals.We found
a low level of declared medical writing assistance, whether
or not articles were based on research with pharmaceutical
sponsorship.
LETTERS
932 JAMA, August 23/30, 2006—Vol 296, No. 8 (Reprinted) ©2006 American Medical Association. All rights reserved.
 at UQ Library on September 21, 2011jama.ama-assn.orgDownloaded from 
Thetrueprevalenceofmedicalwritingassistancecomprises
the prevalence of declared medical writing assistance (6% in
our study) and the prevalence of undeclaredmedical writing
assistance. Estimates for the prevalence of undeclared medi-
calwritingassistancearebasedondifferentinformationsources.
Inonesurvey,7 authorsadmitted thatundeclaredmedicalwrit-
ingassistancewas involved inonly11(1.4%)of809published
articles.Inanothersurvey,8whenauthorswerespecificallyasked
whether they used but did not declare medical writing assis-
tance, only 14 (2%) of 810 authors admitted to this practice.
Anassertion that50%ormoreofdrug-relatedarticles inhigh-
ranking journals are preparedwith undeclaredmedical writ-
ing assistance9 was not supported by direct evidence.
Our resultsmayunderestimate the true prevalence ofmedi-
cal writing assistance in the published medical literature.
First, authors may be unaware of the need to declare writ-
ing assistance. Only 2 of the 10 journals we examined spe-
cifically advised authors to acknowledge writing assistance
(Table). Second, authors may be unwilling to declare writ-
ing assistance because of the controversy surrounding au-
thorship practices,8 particularly the unethical practice of not
declaring assistance (ghostwriting). Third, approximately
40% of authors may be interested in writing assistance to
help them improve manuscript quality and reduce prepa-
ration time.8 Fourth, demand for medical writing services
is growing, with increases in the number of medical writ-
ers and the medical writing services market.10 Fifth, pre-
liminary evidence suggests that not all medical writers fol-
low ethical publication guidelines. A pilot survey ofmedical
writers, who made substantial contributions to manu-
scripts, found that only approximately 55% encouraged au-
thors to follow ethical publication guidelines.11
Our study is limited by our use of high-ranking journals
and original research articles; the prevalence of declaredmedi-
cal writing assistancemay differ formid- to low-ranking jour-
nals and for other article types. Although we used informa-
tion published in the acknowledgment sections, our results
reflect the information that authors and journals chose to pro-
vide, which may be incomplete. Finally, because we did not
attempt to examine the prevalence of undeclared assistance,
additional evidence-based studies are required to quantify its
extent.
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Table. Prevalence of Declared Medical Writing Assistance and Industry-Sponsored Research in 1000 Articles From International,
High-Ranking, Peer-Reviewed Journals*
Journal
2003
Impact
Factor†
Requirement to
Acknowledge
Medical Writer‡
Publication Period
of 100 Articles Examined
No. of Articles
With Declared
Medical Writer
No. of Articles From
Industry-Sponsored
Research
American Journal of Kidney Diseases 3.9 No February 2004 to November 2004 0 8
American Journal of Medicine 4.4 No May 2004 to December 2004 10 8
Archives of General Psychiatry 10.5 No December 2003 to November 2004 8 7
Arthritis Research and Therapy 5.0 Yes June 2003 to December 2004 6 13
Circulation 11.2 No November 2004 to December 2004 4 11
Clinical and Infectious Diseases 5.4 No July 2004 to November 2004 11 22
Diabetes Care 7.5 No August 2004 to November 2004 5 26
Hepatology 9.5 No August 2004 to December 2004 4 3
International Journal of Cancer 4.4 No January 2005 to February 2005§ 10 2
Thorax 4.2 Yes April 2004 to December 2004 2 2
Total (N = 1000) NA NA NA 60 102
Abbreviation: NA, not applicable.
*Articles selected in consecutive reverse order, starting with the most recent online edition, until there were 100 articles per journal.
†From the Thomson Institute for Scientific Information’s Journal Citation Reports.
‡Explicit statement within the journal’s “Instructions to Authors” that medical writing assistance should be acknowledged.
§Online edition for February 2005; available in January 2005.
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CORRECTIONS
Incorrect Data: In the Original Contribution entitled “Fluoxetine After Weight Res-
toration in Anorexia Nervosa” published in the June 14, 2006, issue of JAMA (2006;
295:2605-2612), the boxes in Figure 1 that stated the reasons for premature termi-
nation for participants taking fluoxetine and placebo were switched. In the box de-
scribing reasons for termination forparticipants taking theplacebo,“SuicideAttempt”
was incorrectly substituted for “Clinical Deterioration.” In Tables 1, 3, and the Mea-
sures section, The Yale Brown Cornell Obsessive Compulsive Scale for Eating Disor-
ders should have been termed the Yale-Brown-Cornell Eating Disorder Scale and the
Eating Disorders Inventory should have been termed the Eating Disorder Inventory.
In the Table 2 footnotes, the2 value after “§Proportion of patients with outcome sta-
tus of full recovery, good, or fair vs poor with fluoxetine vs placebo” should have been
2=1.005. In Table 3, the random-effects regression for the fluoxetine group for the
Eating Disorder Inventory bulimia subscale should have been 0.11 rather than −0.11.
Inthe lastparagraphofthearticle, thereferences24,25after“psychological treatments”
should have been numbered 24 and references 26,27 after “olanzapine” should have
been numbered 26. None of these corrections affect the conclusions in the article.
Error in Wording: In the Editorial entitled “Radiosurgery and Whole-Brain Radia-
tion Therapy for Brain Metastases: Either or Both as the Optimal Treatment” pub-
lished in the June 7, 2006, issue of JAMA (2006;295:2535-2536), an error oc-
curred in wording. In the final paragraph on page 2536, the term “stereotactic
radiosurgery” should have been “whole-brain radiation therapy” in both in-
stances. The sentence should have read “Aoyama et al10 have prospectively shown
that withholding whole-brain radiation therapy does not affect survival for pa-
tients who have 4 or fewer brain metastases; these patients have a higher rate of
local brain failure, but apparently withholding whole-brain radiation therapy does
not influence how patients die of their disease.”
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